Microbot Medical Continues to Ramp Up Patient Enrollment in its Pivotal Human Clinical Trial
09 July 2024 - 10:30PM
Microbot Medical Inc. (Nasdaq: MBOT) today announced that Baptist
Hospital of Miami, which includes Miami Cardiac & Vascular
Institute and Miami Cancer Institute, has completed its first
clinical procedure in a patient utilizing the LIBERTY® Endovascular
Robotic Surgical System. The clinical case was performed shortly
after last week’s announcement regarding the participation of
Baptist Hospital of Miami as a clinical trial site. Baptist
Hospital is the second clinical site to perform a clinical
procedure, following the announcement earlier this week of the
first clinical case at Brigham & Women’s Hospital.
The principal investigator at Baptist Hospital of Miami is Dr.
Ripal Gandhi, MD, FSVM, FSIR, who also performed this clinical
case. The trial is part of the Investigational Device Exemption for
LIBERTY®, and the Company expects its results will support the
future submission to the FDA and subsequent commercialization.
“We are very excited to have a hospital of the caliber of
Baptist Hospital of Miami performing clinical cases. It is very
encouraging to see the progress of our clinical study, as within a
couple of weeks we now have two sites actively enrolling patients,”
commented Harel Gadot, CEO, President and Chairman of Microbot
Medical.
About Microbot MedicalMicrobot
Medical Inc. (NASDAQ: MBOT) is a clinical- stage medical device
company that specializes in transformational micro-robotic
technologies, with the goals of improving clinical outcomes for
patients and increasing accessibility through the natural and
artificial lumens within the human body.
The Investigational LIBERTY® Endovascular
Robotic Surgical System aims to improve the way surgical robotics
are being used in endovascular procedures today, by eliminating the
need for large, cumbersome, and expensive capital equipment, while
reducing radiation exposure and physician strain. The Company
believes the LIBERTY® Endovascular Robotic Surgical System’s remote
operation has the potential to be the first system to democratize
endovascular interventional procedures.
Further information about Microbot Medical is
available at http://www.microbotmedical.com.
Safe HarborStatements to future
financial and/or operating results, future growth in research,
technology, clinical development, and potential opportunities for
Microbot Medical Inc. and its subsidiaries, along with other
statements about the future expectations, beliefs, goals, plans, or
prospects expressed by management, constitute forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 and the Federal securities laws. Any statements
that are not historical fact (including, but not limited to
statements that contain words such as “will,” “believes,” “plans,”
“anticipates,” “expects” and “estimates”) should also be considered
to be forward-looking statements. Forward-looking statements
involve risks and uncertainties, including, without limitation,
market conditions, risks inherent in the development and/or
commercialization of the LIBERTY® Endovascular Robotic Surgical
System, the outcome of its studies to evaluate the LIBERTY®
Endovascular Robotic Surgical System, uncertainty in the results of
pre-clinical and clinical trials or regulatory pathways and
regulatory approvals, including whether the Company’s pivotal study
in humans is successful, any failure or inability to recruit
physicians and clinicians to serve as primary investigators to
conduct regulatory studies which could adversely affect or delay
such studies, disruptions resulting from new and ongoing
hostilities between Israel and the Palestinians and other
neighboring countries, any lingering uncertainty resulting from the
COVID-19 pandemic, need and ability to obtain future capital, and
maintenance of intellectual property rights. Additional information
on risks facing Microbot Medical can be found under the heading
“Risk Factors” in Microbot Medical’s periodic reports filed with
the Securities and Exchange Commission (SEC), which are available
on the SEC’s web site at www.sec.gov. Microbot Medical disclaims
any intent or obligation to update these forward-looking
statements, except as required by law.
Investor Contact:
Michal Efraty
IR@microbotmedical.com
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Jul 2023 to Jul 2024